Ridgetech Inc.
- Open
- 1.22
- Day high
- 1.36
- Day low
- 1.22
- Prev close
- 1.25
- Volume
- 248K
- Mkt cap
- $1M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.0
- P/S
- 0.0
- Yield
- —
- Per share
- —
- ▲Insiders net buying $46K over the last 3 months (5 open-market buys, 3 sales)
Ridgetech Inc. (RDGT) is a Healthcare company listed on NASDAQ. The stock is down 99% over the past year. Over the trailing 3 months, insiders filed 5 open-market buys and 3 sales (SEC Form 4).
Ridgetech Inc. (RDGT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RDGT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 30,939 | $1.52 |
| Jul 2, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 10,197 | $1.50 |
| Jun 18, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 57,998 | $1.60 |
| Jun 17, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 8,091 | $1.60 |
| Jun 16, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 6,526 | $1.51 |
| Jun 12, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 19,373 | $1.61 |
| Jun 11, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 25,024 | $1.78 |
| Jun 11, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 14,312 | $1.62 |
Source: RDGT SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
See the full RDGT insider & 13F page →Ridgetech Inc. company profile
Overview
Ridgetech Inc. (NASDAQ:RDGT) is a healthcare distribution company that operates as a holding company through its subsidiaries in the pharmaceutical and healthcare products wholesale and retail market. The company went public on September 12, 2024, making it a recent entrant to the public markets. Ridgetech operates in the critical healthcare supply chain, serving as an intermediary between pharmaceutical manufacturers and healthcare providers, pharmacies, and other end customers who need access to medications and medical supplies.
Business
Ridgetech operates in the medical distribution industry, which serves as the vital link between pharmaceutical manufacturers and healthcare providers. The company functions as a pharmaceutical wholesaler and distributor, purchasing medications and healthcare products in bulk from manufacturers and then distributing them to pharmacies, hospitals, clinics, and other healthcare facilities. The pharmaceutical distribution industry is essential to the healthcare ecosystem because it ensures that medications reach patients efficiently and safely. Distributors like Ridgetech maintain extensive warehouse networks, cold chain storage for temperature-sensitive medications, and sophisticated logistics systems to manage inventory and deliveries. They also provide value-added services such as inventory management, regulatory compliance support, and financial services to their customers. Based on the available financial data, Ridgetech appears to operate primarily as a single business segment focused on pharmaceutical and healthcare product distribution. The company generated approximately $155 million in revenue for fiscal year 2023, indicating it operates at a mid-tier scale within the distribution industry. The business involves both wholesale operations (selling to other distributors or large healthcare systems) and retail distribution (serving individual pharmacies and smaller healthcare providers).
Revenue model
Ridgetech generates revenue through traditional distribution margins, earning the difference between the wholesale price it pays to pharmaceutical manufacturers and the price it charges to its customers. This business model relies on high-volume, low-margin transactions where profitability depends on operational efficiency and scale. The company's customers include independent pharmacies, small hospital systems, long-term care facilities, and other healthcare providers who need reliable access to pharmaceutical products but lack the scale to purchase directly from manufacturers. These customers pay Ridgetech for both the products and the distribution services, which include inventory management, timely delivery, and regulatory compliance support. Several factors can significantly impact Ridgetech's margins and profitability. Positive margin drivers include increasing drug prices (which expand absolute dollar margins), operational efficiency improvements, favorable supplier terms through volume commitments, and value-added services that command premium pricing. Negative margin pressures come from intense competition with larger distributors like McKesson, Cardinal Health, and AmerisourceBergen, which can leverage greater scale for better supplier terms. Generic drug pricing deflation, increased regulatory compliance costs, customer consolidation leading to greater bargaining power, and the need for technology investments to remain competitive also compress margins. The company's financial performance shows the challenges of this business model, with negative operating cash flows and net losses indicating either operational inefficiencies, competitive pressures, or investments in growth that have not yet generated positive returns.
Competitive moat
Ridgetech operates in a highly competitive industry with limited sustainable competitive advantages. The pharmaceutical distribution business is characterized by relatively low barriers to entry for smaller regional players, though significant capital requirements exist for larger-scale operations. The company's potential moats are quite narrow. Geographic concentration in specific regions could provide some competitive protection if Ridgetech has established strong relationships with local healthcare providers and can offer superior service levels. Regulatory expertise and compliance capabilities represent another potential advantage, as pharmaceutical distribution requires extensive knowledge of FDA regulations, DEA requirements, and state-level licensing. Customer relationships built over time with independent pharmacies and smaller healthcare systems could create switching costs, particularly if Ridgetech provides integrated services beyond basic distribution. However, these moats are relatively weak compared to the dominant position held by the "Big Three" distributors (McKesson, Cardinal Health, and AmerisourceBergen), which control approximately 90% of the U.S. pharmaceutical distribution market. These large competitors possess significant advantages including superior economies of scale, stronger supplier relationships, more extensive geographic coverage, and greater financial resources for technology investments and acquisitions. The primary competitive threats come from continued consolidation in the industry, direct-to-pharmacy programs from manufacturers, and the potential for larger distributors to expand into Ridgetech's markets. Additionally, the growth of specialty pharmaceuticals and biosimilars is changing distribution dynamics, often favoring larger players with specialized capabilities.
Risks & safety
Ridgetech exhibits significant financial stress indicators that suggest a narrow margin of safety for investors. • Cash burn and solvency: The company generated negative free cash flow of -$4.1 million in FY2023 and -$5.2 million in recent quarters, indicating ongoing cash consumption. With approximately $20.1 million in cash and short-term investments as of Q1 2024, the company has roughly 12-18 months of runway at current burn rates. • Debt and leverage: Debt-to-equity ratio of 2.76x indicates high leverage, though specific debt amounts are not clearly disclosed in the available data. Current ratio of 0.94x shows current liabilities slightly exceed current assets, creating potential liquidity pressure. • Valuation metrics: Trading at negative P/E ratios due to losses, with price-to-book ratio of 0.31x suggesting the stock trades below book value. The small market cap of approximately $5.6 million indicates limited institutional interest and potential liquidity issues. • Other considerations: Recent IPO status means limited trading history and price discovery. Negative EBITDA margins and consistent losses over multiple periods indicate fundamental operational challenges that may require significant capital or operational restructuring to resolve.
Recent development
Due to the lack of available earnings call transcripts and the company's recent IPO status in September 2024, detailed information about strategic initiatives and recent developments is limited. However, the financial data reveals several key trends over the past two years. The company has struggled with profitability, showing consistent net losses across all reported periods. Revenue appeared relatively stable around $155 million annually in 2023, but quarterly revenue figures suggest some volatility with Q1 2024 showing higher revenue ($38 million) compared to subsequent quarters ($35.6 million in Q2 and Q3). This pattern could indicate seasonal fluctuations typical in pharmaceutical distribution or potential customer losses. The decision to go public in September 2024 represents the most significant recent development, likely aimed at raising capital to address the ongoing cash burn and fund growth initiatives. The timing of the IPO, despite the company's negative profitability, suggests either acquisition interest, the need for capital to avoid financial distress, or confidence in a turnaround strategy that management expects to implement with public market funding. The deteriorating cash flow trends, with free cash flow worsening from -$4.1 million in FY2023 to over -$5 million in recent quarters, indicate that operational challenges have persisted or intensified following the public offering.
RDGT company profile · for informational purposes only — not investment advice.
Track RDGT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free